ANTAGONISTS OF IL-6 TO PREVENT OR TREAT THROMBOSIS
10 Assignments
0 Petitions
Accused Products
Abstract
The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al.
-
Citations
110 Claims
-
1-90. -90. (canceled)
-
91. A method of reducing the risk of hypercoagulation or thrombosis in a subject having an elevated IL-6 level and an elevated D-dimer level by reducing the level of serum D-dimer in said subject, comprising administering to the subject an amount of an IL-6 antagonist, wherein said IL-6 antagonist is an antibody or antibody fragment that specifically binds human IL-6, wherein said antibody or antibody fragment comprises (i) the VL CDRs in SEQ ID NO:
- 23, 24 and 25 and the VH CDRs in SEQ ID NO;
26-28;
(ii) the VL CDRs in SEQ ID NO;
39, 40 and 41 and the VH CDRs in SEQ ID NO;
42, 43 and 44;
(iii) the VL CDRs in SEQ ID NO;
55, 56 and 57 and the VH CDRs in SEQ ID NO;
58, 59 and 60;
(iv) the VL CDRs in SEQ ID NO;
71, 72 and 73 and the VH CDRs in SEQ ID NO;
74, 75 and 76;
(v) the VL CDRs in SEQ ID NO;
87, 88 and 89 and the VH CDRs in SEQ ID NO;
90, 91 and 92;
(vi) the VL CDRs in SEQ ID NO;
103, 104 and 105 and the VH CDRs in SEQ ID NO;
106, 107 and 108;
(vii) the VL CDRs in SEQ ID NO;
124, 125 and 126 and the VH CDRs in SEQ ID NO;
127, 128 and 129;
(viii) the VL CDRs in SEQ ID NO;
140, 141 and 142 and the VH CDRs in SEQ ID NO;
143, 144 and 145;
(ix) the VL CDRs in SEQ ID NO;
156, 157 and 158 and the VH CDRs in SEQ ID NO;
159, 160 and 161;
(x) the VL CDRs in SEQ ID NO;
172, 173 and 174 and the VH CDRs in SEQ ID NO;
175, 176 and 177;
(xi) the VL CDRs in SEQ ID NO;
188, 189 and 190 and the VH CDRs in SEQ ID NO;
191, 192 and 193;
(xii) the VL CDRs in SEQ ID NO;
204, 205 and 206 and the VH CDRs in SEQ ID NO;
207, 208 and 209;
(xiii) the VL CDRs in SEQ ID NO;
220, 221 and 222 and the VH CDRs in SEQ ID NO;
223, 224 and 225;
(xiv) the VL CDRs in SEQ ID NO;
236, 237 and 238 and the VH CDRs in SEQ ID NO;
239, 240 and 241;
(xv) the VL CDRs in SEQ ID NO;
252, 253 and 254 and the VH CDRs in SEQ ID NO;
255, 256 and 257;
(xvi) the VL CDRs in SEQ ID NO;
268, 269 and 270 and the VH CDRs in SEQ ID NO;
271, 272 and 273;
(xvii) the VL CDRs in SEQ ID NO;
284, 285 and 286 and the VH CDRs in SEQ ID NO;
287, 288 and 289;
(xviii) the VL CDRs in SEQ ID NO;
300, 301 and 302 and the VH CDRs in SEQ ID NO;
303, 304 and 305;
(xix) the VL CDRs in SEQ ID NO;
316, 317 and 318 and the VH CDRs in SEQ ID NO;
319, 320 and 321;
(xx) the VL CDRs in SEQ ID NO;
332, 333 and 334 and the VH CDRs in SEQ ID NO;
335, 336 and 337;
(xxi) the VL CDRs in SEQ ID NO;
348, 349 and 350 and the VH CDRs in SEQ ID NO;
351, 352 and 353;
(xxii) the VL CDRs in SEQ ID NO;
364, 365 and 366 and the VH CDRs in SEQ ID NO;
367, 368 and 369;
(xxiii) the VL CDRs in SEQ ID NO;
380, 381 and 382 and the VH CDRs in SEQ ID NO;
383, 384 and 385;
(xxiv) the VL CDRs in SEQ ID NO;
396, 397, and 398 and the VH CDRs in SEQ ID NO;
399, 400 and 401;
(xxv) the VL CDRs in SEQ ID NO;
412, 413 and 414 and the VH CDRs in SEQ ID NO;
415, 416 and 417;
(xxvi) the VL CDRs in SEQ ID NO;
428, 429 and 430 and the VH CDRs in SEQ ID NO;
431, 432 and 433;
(xxvii) the VL CDRs in SEQ ID NO;
444, 445 and 446 and the VH CDRs in SEQ ID NO;
447, 448 and 449;
(xxviii) the VL CDRs in SEQ ID NO;
460, 461 and 462 and the VH CDRs in SEQ ID NO;
463, 464 and 465;
(xxix) the VL CDRs in SEQ ID NO;
476, 477 and 478 and the VH CDRs in SEQ ID NO;
479, 480 and 481;
(xxx) the VL CDRs in SEQ ID NO;
492, 493 and 494 and the VH CDRs in SEQ ID NO;
495, 496, and 497;
(xxxi) the VL CDRs in SEQ ID NO;
508, 509 and 510 and the VH CDRs in SEQ ID NO;
511, 512 and 513;
(xxxii) the VL CDRs in SEQ ID NO;
524, 525 and 526 and the VH CDRs in SEQ ID NO;
527, 528 and 529;
(xxxiii) the VL CDRs in SEQ ID NO;
540, 541 and 542 and the VH CDRs in SEQ ID NO;
543, 544 and 545;
(xxxiv) the VL CDRs in SEQ ID NO;
556, 557 and 558 and the VH CDRs in SEQ ID NO;
559, 560 and 561;
or (xxxv) the VL CDRs in SEQ ID NO;
572, 573 and 574 and the VH CDRs in SEQ ID NO;
575, 576 and 577, and which antibody or fragment is administered in an amount effective to reduce the level amount of serum D-dimer thereby reducing the risk of hypercoagulation or thrombosis in said subject. - View Dependent Claims (93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110)
- 23, 24 and 25 and the VH CDRs in SEQ ID NO;
Specification